National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2016 (No. 2) (PB 12 of 2016) (Cth)

PB 12 of 2016

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2016 (No. 2)

National Health Act 1953

I, PENNY SHAKESPEARE, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated                  25 February 2016

PENNY SHAKESPEARE
First Assistant Secretary
Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

Amendment instrument – Pharmaceutical benefits – early supply

1          Name of Instrument

(1)      This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2016 (No. 2)

(2)This Instrument may also be cited as PB 12 of 2016.

2          Commencement

This Instrument commences on 1 March 2016.

3          Amendment of PB 120 of 2015

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

Schedule 1        Amendments

1. Schedule 1, after entry for Dabrafenib in the form Capsule 75 mg (as mesilate)

   insert:

Daclatasvir	Tablet 30 mg	20	28	5
Daclatasvir	Tablet 60 mg	20	28	5

1. Schedule 1, after entry for Empagliflozin in the form Tablet 25 mg

   insert:

Empagliflozin with metformin	Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride	20	60	5
Empagliflozin with metformin	Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride	20	60	5
Empagliflozin with metformin	Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride	20	60	5
Empagliflozin with metformin	Tablet containing 12.5 mg empagliflozin with 1g metformin hydrochloride	20	60	5

1. Schedule 1, after entry for Lansoprazole in the form Tablet 30 mg (orally disintegrating) [Number of Repeats: 5]

   insert:

Ledipasvir with sofosbuvir Tablet containing 90 mg ledipasvir with 400 mg sofosbuvir 20 28 5

1. Schedule 1, after entry for Reboxetine

   insert:

Ribavirin	Tablet 400 mg	20	28	5
Ribavirin	Tablet 600 mg	20	28	5

1. Schedule 1, after entry for Sitagliptin with metformin in the form Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 850 mg metformin hydrochloride

   insert:

Sofosbuvir Tablet 400 mg 20 28 5